Initial experience with the combination of atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma progressing after tyrosine kinase inhibitor therapy: A multicenter prospective observational study
Abstract:Background
There is no evidence for the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma previously treated with tyrosine kinase inhibitors (TKIs).
Methods
Twelve patients treated with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) and previously treated with TKIs were enrolled in the study.
Results
The treatment lines ranged from second line to sixth line. HCC staging was Barcelona Clinic Liver Cancer (BCLC) stage B in four cases a… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.